Valuation: Rapport Therapeutics, Inc.

Market Cap 1.92B 1.68B 1.55B 1.43B 2.69B 185B 2.75B 18.51B 7.27B 90.47B 7.21B 7.05B 312B P/E 2026 *
-12.3x
P/E 2027 * -10.1x
Enterprise Value 1.68B 1.47B 1.35B 1.25B 2.35B 161B 2.4B 16.17B 6.35B 79B 6.29B 6.16B 272B EV / Sales 2026 *
83.8x
EV / Sales 2027 * -
Free-Float
95.38%
Yield 2026 *
-
Yield 2027 * -
1 day+6.20%
1 week+1.36%
Current month+2.28%
1 month+10.73%
3 months+7.79%
6 months+58.97%
Current year+40.47%
1 week 38.62
Extreme 38.62
42.72
1 month 36.46
Extreme 36.46
43.76
Current year 25.21
Extreme 25.21
43.76
1 year 13.62
Extreme 13.62
43.76
3 years 6.43
Extreme 6.43
43.76
5 years 6.43
Extreme 6.43
43.76
10 years 6.43
Extreme 6.43
43.76
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 61 01/01/2023
Chief Executive Officer 48 01/02/2023
Director of Finance/CFO 58 01/11/2023
Director TitleAgeSince
Director/Board Member 61 23/08/2023
Director/Board Member 48 01/03/2023
Director/Board Member 54 01/02/2022
Date Insider Type Main position Quantity % Market Cap.
7/14/26 A Sell

Chief Executive Officer

-8,210 0.0172%
6/30/26 A Sell

Chief Operating Officer

-10,000 0.0209%
6/29/26 A Sell

Chief Executive Officer

-8,220 0.0172%
Change 5-day change 1-year change 3-year change Capi.($)
+6.20%+1.36%+180.03% - 1.92B
-1.29%-2.54%-0.35%+4.30% 49.7B
+3.90%-2.60%+384.79%+598.27% 38.09B
-1.70%+3.03%+11.77%+58.93% 35.29B
-2.01%-1.30%+30.02%-6.71% 35.13B
+0.06%+1.56%+4.41%+27.42% 27.22B
+0.46%-5.24% - - 16.14B
-0.04%+0.42%+70.80%+121.10% 15.36B
+1.12%+2.15%+16.24%+19.12% 13.89B
0.00%+0.73%+18.02%-30.96% 13.02B
Average +0.67%-0.97%+79.53%+98.93% 24.58B
Weighted average by Cap. -0.04%-0.67%+78.93%+119.96%

Financials

2026 *2027 *
Net sales 20M 17.49M 16.14M 14.87M 28.04M 1.93B 28.65M 193M 75.77M 943M 75.11M 73.45M 3.25B -
Net income -167M -146M -134M -124M -233M -16.03B -239M -1.61B -631M -7.85B -625M -611M -27.03B -220M -192M -177M -163M -308M -21.16B -315M -2.12B -833M -10.36B -826M -807M -35.69B
Net Debt -243M -213M -196M -181M -341M -23.42B -349M -2.35B -922M -11.47B -914M -894M -39.5B -336M -294M -271M -250M -471M -32.35B -481M -3.24B -1.27B -15.84B -1.26B -1.23B -54.55B
Logo Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for patients with focal onset seizures, primary generalized tonic-clonic seizures and bipolar mania. Additional preclinical and late-stage discovery stage programs are also underway, including chronic pain and hearing disorders.
Employees
84
Date Price Change Volume
17/07/26 $42.62 +6.20% 470,023
16/07/26 $40.13 +0.50% 350,671
15/07/26 $39.93 -3.69% 256,352
14/07/26 $41.46 +2.14% 404,952
13/07/26 $40.59 -2.78% 364,526
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
40.13USD
Average target price
56.64USD
Spread / Average Target
+41.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RAPP Stock